Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 18,052 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, January 16th, Group Gp Lp Column III purchased 2,562 shares of Surrozen stock. The stock was bought at an average cost of $20.00 per share, for a total transaction of $51,240.00.
• On Thursday, January 15th, Group Gp Lp Column III purchased 11,893 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III acquired 5,523 shares of Surrozen stock. The shares were bought at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The stock was bought at an average price of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The shares were bought at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The stock was bought at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

NASDAQ SRZN opened at $17.98 on Wednesday. The stock’s 50 day simple moving average is $18.98 and its 200-day simple moving average is $14.13. The company has a market cap of $154.09 million, a PE ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million during the quarter. On average, equities research analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Analysts Set New Price Targets

Several brokerages recently issued reports on SRZN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Trading of Surrozen

Several institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC lifted its holdings in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Surrozen in the 3rd quarter valued at $621,000. Armistice Capital LLC purchased a new position in shares of Surrozen during the 2nd quarter worth $536,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen during the 3rd quarter worth about $889,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.